// App-Quantinova.ai

576 : Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC).

Researchers

Presenter

  • Stefania Redana

Principal Investigators

  • Elisavet Papadimitraki

  • David Odhiambo Okonji

  • Komel Khabra

  • Eirini Thanopoulou

  • Jaseela Chiramel

  • Panagiotis Papanastasopoulos

  • Andrew M. Wardley

  • Martin S. Hogg

  • Sacha Jon Howell

  • Giorgia Zucchini

  • Laura M. Kenny

  • Alistair E. Ring

  • Stephen R. D. Johnston

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Surrey and Sussex Healthcare NHS Trust, Guilford, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Imperial College, London, United Kingdom

  • The Christie Hospital, Huddersfield, United Kingdom

  • Rosemere Cancer Center, Manchester, United Kingdom

  • University of Manchester, Manchester, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Exemestane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved